ES2542344T3 - Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares - Google Patents

Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares Download PDF

Info

Publication number
ES2542344T3
ES2542344T3 ES07804842.8T ES07804842T ES2542344T3 ES 2542344 T3 ES2542344 T3 ES 2542344T3 ES 07804842 T ES07804842 T ES 07804842T ES 2542344 T3 ES2542344 T3 ES 2542344T3
Authority
ES
Spain
Prior art keywords
compound
compounds
treatment
cell proliferative
ppg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07804842.8T
Other languages
English (en)
Spanish (es)
Inventor
Eliahu Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaremed Ltd
Original Assignee
Novaremed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd filed Critical Novaremed Ltd
Application granted granted Critical
Publication of ES2542344T3 publication Critical patent/ES2542344T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES07804842.8T 2006-05-09 2007-05-09 Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares Active ES2542344T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79910306P 2006-05-09 2006-05-09
US799103P 2006-05-09
PCT/IB2007/002471 WO2007129226A2 (en) 2006-05-09 2007-05-09 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders

Publications (1)

Publication Number Publication Date
ES2542344T3 true ES2542344T3 (es) 2015-08-04

Family

ID=38668152

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07804842.8T Active ES2542344T3 (es) 2006-05-09 2007-05-09 Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares

Country Status (12)

Country Link
US (3) US20090306214A1 (https=)
EP (1) EP2026775B1 (https=)
JP (1) JP5225264B2 (https=)
AU (1) AU2007246779B2 (https=)
CA (1) CA2651375C (https=)
DK (1) DK2026775T3 (https=)
ES (1) ES2542344T3 (https=)
HU (1) HUE026820T2 (https=)
IL (1) IL195152A (https=)
PL (1) PL2026775T3 (https=)
PT (1) PT2026775E (https=)
WO (1) WO2007129226A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642290B2 (en) * 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
CN102821761B (zh) * 2009-09-09 2015-06-10 诺瓦麦有限公司 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022019920A1 (en) 2020-07-24 2022-01-27 Verastem, Inc. Treatment of cancers using pi3 kinase isoform modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1908322A (en) * 1932-04-07 1933-05-09 Claude R Cook Weed puller
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7642290B2 (en) * 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法

Also Published As

Publication number Publication date
CA2651375A1 (en) 2007-11-15
WO2007129226A2 (en) 2007-11-15
AU2007246779B2 (en) 2013-11-28
IL195152A0 (en) 2009-09-22
PL2026775T3 (pl) 2015-12-31
JP5225264B2 (ja) 2013-07-03
US20090306214A1 (en) 2009-12-10
PT2026775E (pt) 2015-08-05
DK2026775T3 (en) 2015-06-29
EP2026775A2 (en) 2009-02-25
HUE026820T2 (en) 2016-07-28
JP2009536191A (ja) 2009-10-08
IL195152A (en) 2015-10-29
CA2651375C (en) 2015-12-22
US20120108666A1 (en) 2012-05-03
EP2026775B1 (en) 2015-04-29
AU2007246779A1 (en) 2007-11-15
WO2007129226A3 (en) 2008-05-08
US20140039060A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
ES2542344T3 (es) Uso de inhibidores de tirosina cinasa Syk para el tratamiento de trastornos proliferativos celulares
ES2371191T3 (es) Compuestos citotóxicos.
JP2010526080A (ja) ホノキオール類縁体および癌治療へのそれらの使用
ES2469797T3 (es) Compuestos farmacéuticos
HUP9901344A2 (hu) Radicicol származékok és ezeket tartalmazó gyógyszerkészítmények
CN115052879B (zh) 由c20修饰盐霉素衍生物组成的化合物、其获得方法、包含其的组合物、该化合物的用途和获得中间产物的方法
ES2686683T3 (es) Derivados de tieno-indol funcionalizados
WO2020252398A1 (en) Proteolysis-targeting protacs inducing degradation of c-mic protein
CA2338000C (en) Water-soluble 4-thio-maleimido derivatives and methods for their production
Chmielewski et al. A hybrid macrocycle containing benzene and pyridine subunits is a better anion receptor than both its homoaromatic congeners
US20070259858A1 (en) Novel bis-pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates and a process for the preparation thereof
KR20130118731A (ko) 항증식성 질환 치료에 사용하기 위한 ｐｉ3ｋ 억제제로서 피페라지노트리아진
ES2373644T3 (es) Uso de derivados de ciclopenta[g]quinazolina para el tratamiento del c�?ncer.
EP2701504A1 (en) Derivatives of sulindac, use thereof and preparation thereof
Martelli et al. N, N-bis (cyclohexanol) amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors
Kamal et al. Synthesis and biological evaluation of cinnamido linked pyrrolo [2, 1-c][1, 4] benzodiazepines as antimitotic agents
EP1163262B1 (en) Phenylalanine derivatives
CN113439084B (zh) 倍癌霉素类似物
AU2004257012B2 (en) Fluorocombretastatin and derivatives thereof
ES2948846T3 (es) Derivado peptídico y uso del mismo
Antoszczak et al. Differences in Antiproliferative Activity Between Salinomycin-AZT Conjugates Obtained via ‘Click’and Esterification Reactions
Kotoku et al. Structure‐activity relationships study of bastadin 6, an anti‐angiogenic brominated‐tyrosine derived metabolite from marine sponge
ES2735375T3 (es) Derivados funcionalizados de morfolinil antraciclina
Yao et al. Synthesis and evaluation of novel amino pyrimidine derivatives containing sulfonamide and their application as EGFR inhibitors
Hosseini et al. Design of chiral 2-oxazoline-based amino acid bioConjugates as anticancer agents: Synthesis, in vitro anticancer activity, ADMET prediction with molecular docking and molecular dynamic simulation insights